The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

COVID-19 'war games': the computer program that could help save your job

Wed, 11th Nov 2020 12:23

* Tech firm creates game to simulate impact of COVID layoffs

* 'Broad-front' cost-cutting strategy seen as more effective

* World of work on brink of revolution, creator says

By Sinead Cruise

LONDON, Nov 11 (Reuters) - Bank of England Chief Economist
Andy Haldane has signed up to judge the winner of a 'war game'
designed to help firms find alternatives to mass layoffs in the
face of a coronavirus-driven slowdown.

Confronted with the most unpredictable pandemic in memory,
cost-conscious firms have already axed millions of staff
worldwide, while UK redundancies hit a record high of 314,000 in
the quarter to Sept. 30, official data showed on Tuesday.

Unilever-owned tech firm uFlexReward created the
COVID-19 War Game to allow executives to explore the impact of
huge job cuts on their future earnings prospects.

"Many companies across the UK are facing financial strains
as a result of the COVID crisis," Haldane told Reuters.

"Simulation tools can help us understand how best to
alleviate these strains while preserving jobs, in a way that
helps both businesses when making difficult commercial decisions
and policymakers when making difficult economic decisions."

The game, designed during Britain's first lockdown this year
and available free to play on the uFlexReward website, calls on
players to devise a strategy to cut people costs of a fictional
firm by 20%.

Participants weigh up the pros and cons of large-scale
redundancies versus alternatives, for the long-term benefit of
the firm as well as the broader economy.

It collates staff salaries, pensions, bonuses and share
awards into one real-time cost-base, helping players see
different ways of trimming overheads more clearly.

This can include making lots of smaller cost cuts in a
so-called 'broad-front' approach, rather than one large saving
in more focused cuts like scrapping entire business units or the
staff bonus pool.

Financial firms have historically slashed highly paid
workforces on the eve of recession, only to rehire rapidly when
the economy rebounds.

Swapping this convention for a broad-front approach could
minimise the risks that employers end up understaffed and
under-skilled when the recovery kicks off, uFlexReward Chief
Executive Ken Charman said.

'CHANGE IS COMING'

Employers in multiple sectors are facing the prospect of a
broader revolution in the world of work, triggered by technology
and mass remote working.

"We are still stuck in a very Victorian view of what work is
- with fixed working days, for a single employer and in a
typically narrow role," Charman said.

"But change is coming that will allow people to be several
things at once ... if companies lose people who are highly
trained, experienced and loyal, they won't get them back," he
said.

Charman hopes the game might persuade employers to waive or
cut dividends as well as executive pay increases, and offer
job-sharing, reduced hours or part-time roles with flexibility
to work elsewhere to staff who might otherwise end up
unemployed.

Pushing through alternatives to mass layoffs will require
strong leadership and communication, particularly when thousands
of employee contracts need to be renegotiated, but retaining
staff could leave firms better placed when the recovery begins,
Charman said.

"Executives need to be willing to abandon the old
conventions; there will be resistance and they've got to be able
to convince people this is in their best interests," he said.

"Employers, big companies and big financial institutions are
part of our critical national infrastructure as much as the
National Grid. They are the engines of our growth, but they are
under threat."

Judging of the head-to-head version of the game, featuring
teams made up of executives from Unilever and NYSE-listed
technology services provider Endava, will take place on
Dec. 3.

Together with Haldane, AstraZeneca senior vice
president of reward and inclusion Rebekah Martin, Unilever head
of global reward Constantina Tribou, and author David Goodhart
are among those judging the strategies.
($1 = 0.7706 pounds)
(Reporting by Sinead Cruise; Editing by Jan Harvey)

More News
8 Feb 2024 08:59

LONDON MARKET OPEN: Unilever up on buyback; BAT ups dividend

(Alliance News) - THE FTSE 100 in London opened slightly higher on Thursday, with earnings from British American Tobacco and Unilever boosting the index.

Read more
8 Feb 2024 08:44

TOP NEWS: AstraZeneca confident after 2023 profit more than doubles

(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.

Read more
8 Feb 2024 07:58

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.

Read more
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more
2 Feb 2024 06:22

TOP NEWS: US sends drugmakers initial offers in Medicare price talks

(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

Read more
1 Feb 2024 15:52

UK earnings, trading statements calendar - next 7 days

Friday 2 February 
YouGov PLCTrading Statement
Monday 5 February 
Home REIT PLCTrading Statement
Porvair PLCFull Year Results
Trident Royalties PLCTrading Statement
Vodafone Group PLCTrading Statement
Tuesday 6 February 
Alumasc Group PLCHalf Year Results
BP PLCFull Year Results
Filtronic PLCHalf Year Results
Mattioli Woods PLCHalf Year Results
Renishaw PLCHalf Year Results
Virgin Money UK PLCTrading Statement
Wednesday 7 February 
Ashmore Group PLCHalf Year Results
Barratt Developments PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Phoenix Spree Deutschland LtdTrading Statement
PZ Cussons PLCHalf Year Results
Smurfit Kappa Group PLCFull Year Results
UK Commercial Property REIT LtdTrading Statement
Thursday 8 February 
Anglo American PLCTrading Statement
AstraZeneca PLCFull Year Results
British American Tobacco PLCFull Year Results
Compass Group PLCTrading Statement
Redrow PLCHalf Year Results
SSE PLCTrading Statement
Unilever PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.